News & Announcements

By Joe Banks, 23andMe Tech Lead Editor’s note: This post by 23andMe’s Joe Banks, first appeared on 23andMe’s engineering blog. We’re reprinting an excerpt of it here to highlight issues...

Like most offices in Silicon Valley, these days 23andMe’s headquarters is largely vacant as employees have adjusted to working from home during the pandemic. But that hasn’t stopped us all...

23andMe recently received two additional privacy certifications from third-party auditors, while successfully re-certifying an existing security certification.  ISO certifications are awarded after extensive audits by independent third-parties. An international standard-setting...

Studying the impact of direct-to-consumer genetic testing on consumers, 23andMe scientists found that people who received information about genetic risk for a certain type of blood clots, found it useful, and in some cases, took actions to lower their risk.

Starting today, we are offering current 23andMe health service customers in the U.S. access to 23andMe+, a new annual membership. This membership provides customers with exclusive access to genetic reports,...

Last June, following the tragic deaths of George Floyd and so many others in the Black community, our CEO pledged to hold ourselves accountable to make improvements to ensure our...

Jamie's experience volunteering at Camp Champ helped to lead 23andMe to add a new Volunteer Time Off benefit for all its employees.

The FDA granted 23andMe clearance to offer a pharmacogentics report on two commonly prescribed medications, one prescribed for heart conditions, and the other for depression.

A drug to fight cancer will be the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration as the two companies announced that the new therapy will begin clinical trials.

We sit down for a chat with L. Okey Onyejekwe Jr., 23andMe's new vice president of Consumer Clinical Operations & Medical Affairs.